No Image Available

Superficial vein

VenaSeal™ closure system

<p>The VenaSeal™ closure system uses a proprietary medical adhesive to treat patients with superficial vein disease.</p>

Ordering information
Contact a representative

UnitedHealthcare (UHC) has expanded its commercial coverage for venous disease treatments to include the VenaSeal™ closure system.

Effective July 1, 2025

Read the UHC policy (open in new window)

How it works

Immediate superficial vein closure

Watch as Dr. Kathleen Gibson delivers immediate and lasting vein closure with our proprietary medical adhesive.1–5

Procedural efficiencies

View a VenaSeal™ closure system procedure animation to see how the single, double, and triple segment treatment options work.

Patient impact

Steve’s story

Hear about Steve’s experience with the VenaSeal™ closure system.

Heather’s story

Hear about Heather’s experience with the VenaSeal™ closure system.

The VenaSeal™ closure system procedure offers:

  • Rapid return to normal activities after treatment1,3
  • Minimized pain, tenderness, and ecchymosis3
  • Significant improvements in quality of life6

The VenaSeal™ closure system procedure eliminates2,4:

  • Tumescent anesthesia
  • Thermal nerve injury
  • Post-procedure compression stockings†

Benefits

Maximize length of treated vein.

  • Access the most distal point of reflux with no risk of thermal injury.1
  • A moderate correlation was demonstrated between diseased vein treatment length and symptom improvement.†,6
  • Physicians observed a decreased time to wound healing with VenaSeal™ closure system compared to radiofrequency ablation.‡,7

Maximize patient comfort and recovery.

  • Minimized pain, tenderness, and ecchymosis compared to endothermal ablation8
  • Rapid return to work and normal activities3
  • No post-procedure compression stockings§,2,4

Maximize efficiencies.

  • More predictable workflow than endothermal therapies with fewer unplanned visits9
  • Simple, segmental procedure1
  • Single, double, and triple segment treatment options

Get great outcomes.

  • 94.6% vein closure at five years5
  • 0 DVT (deep vein thrombosis)5
  • 0 PE (pulmonary embolism)5
  • Significant improvements in quality of life6
View an illustration of VenaSeal™ adhesive being placed in the vein via a small catheter.

Precision

The proprietary catheter is highly visible under ultrasound, allowing precise delivery of the adhesive. The dispensing gun precisely controls the amount of adhesive, delivering 0.10 mL aliquots with each trigger pull.

View polymerization of the VenaSeal™ adhesive at 0, 24, and 54 seconds.

Polymerization

Upon contact with blood, the adhesive begins to bond with the intima, and compression is applied to close the vein. The adhesive was designed to remain permanently in the diseased vein and is encapsulated by chronic fibrosis.7

See a gloved hand holding a VenaSeal™ adhesive bottle with syringe.

Viscosity

The viscosity of the adhesive is specifically designed to minimize migration and embolization.

A man in a blue t-shirt and shorts stands in a pose while taking a yoga class.

Flexibility

The adhesive is designed to be soft and flexible and less likely to be felt by the patient.

Clinical evidence

Great outcomes

Long-term evidence with high clinical standards

View the evidence

9 of 10

patients would choose VenaSeal™ procedure again at five years5

75%

improvement in VCSS scores at five years5

94.6%

closure rate at five years5

System components

  1. Adhesive
  2. Plunger
  3. Release button
  4. Trigger
  5. Dispensing tip
  6. Catheter
This is a picture of the VenaSeal™ closure system with callouts to detail its separate components.

Kit specifications

VenaSeal™ adhesive

Five mL of the VenaSeal™ adhesive (a specially formulated n-butyl-2-cyanoacrylate) is contained within a screw-capped vial.

Dispenser gun

The dispenser gun consists of a pistol-type ergonomic handle with an integrated barrel and trigger. Each depression of the trigger delivers a controlled 0.10 mL (range: 0.06–0.12 mL) amount of adhesive.
Catheter

The catheter is 5 Fr with an effective length of 91 cm, laser markings at 3 cm and 85 cm from the tip, and high echogenic visibility.
Introducer

The introducer is 7 Fr with an effective length of 80 cm, with 10 mm spaced circumferential markings along its length for measuring retraction length during the VenaSeal™ procedure.
Dilator

The dilator is 5 Fr with an effective length of 87 cm.
Syringe

The 3 mL syringes are graduated Monoject™* luer-lock syringes, each with a standard threaded luer-lock connector.
Dispenser tips

The dispenser tips are each comprised of a stainless steel, 1.5 mm ID, 3.8 cm length hypotube with a luer-lock connector.
Guidewire

The guidewire is a 0.035 in, 180 cm straight floppy-tip guidewire.

Ordering information

VenaSeal™ system

Item number Description
VS-404 Glass vial with 5 mL adhesive, dispenser gun, 5 Fr x 91 cm catheter, 7 Fr x 80 cm introducer, 5 Fr x 87 cm dilator, (2) 3 mL syringes, (2) 14 ga dispenser tips, guidewire: 0.035 in, (0.89 mm) 180 cm straight floppy-tip

 

VenaSeal™ system accessories

Item number Description
CFP Procedure pack — scalpel, surgical marking pen, probe cover, table cover, plastic clamp towel, custom label, sharps block, skin closure strip, gowns, dry sponge sticks, bowls, drapes, table cover tapes, needles, and more
MIS-7F07 Micro introducer sheath set — 7 Fr x 7 cm, 21 ga TW needle, guidewire: 0.018 in x 45 cm, single-ended: straight
MIS-7F11 Micro introducer sheath set — 7 Fr x 11 cm, 21 ga TW needle, guidewire: 0.018 in x 45 cm, single-ended: straight
MIS-6F07 Micro introducer sheath set — 6 Fr x 7 cm, 21 ga TW needle, guidewire: 0.018 in, 45 cm, single-ended: straight
MIS-6F11 Micro introducer sheath set — 6 Fr x 11 cm, 21 ga x TW needle, guidewire: 0.018 in, 45 cm, single-ended: straight
IS-7F07 Introducer sheath set — 7 Fr x 7 cm, 19 ga UTW needle, guidewire: 0.035 in x 45 cm, J / straight double-ended
IS-7F11 Introducer sheath set — 7 Fr x 11 cm, 19 ga UTW needle, guidewire: 0.035 in x 45 cm, J / straight double-ended
MPK-5F Micro puncture kit — 5 Fr, 21 ga TW needle, guidewire: 0.018 in x 45 cm, single-ended: straight
AN-19G Percutaneous entry needle — 19 ga, length: 2.75 in, UTW
AN-19GE Percutaneous entry needle — 19 ga, length: 2.75 in, UTW echogenic tip
GW-018-45-SS Guidewire — diameter: 0.018 in, length: 45 cm, single-ended: straight, fixed core, PTFE coated
GW-035-45 Guidewire — diameter: 0.035 in, length: 45 cm, double-ended: 3 mm J and straight, fixed core, PTFE coated
PC-6X96 Ultrasound probe cover

 

Related links

Similar products

TM* Third-party brands are trademarks of their respective owners.

† Demonstrated in C2–C4 patients.

‡ Based on multi-center retrospective cohort study of 119 patients with CEAP class 6 venous ulcers.

§ Some patients may benefit from the use of compression stockings post-procedure.

  1. Morrison N, Gibson K, McEnroe S, et al. Randomized trial comparing cyanoacrylate embolization and radiofrequency ablation for incompetent great saphenous veins (VeClose). J Vasc Surg. 2015;61(4):985–994. doi:10.1016/j.jvs.2014.11.071.
  2. Proebstle T, Alm J, Dimitri S, et al. Three-year follow-up results of the prospective European Multicenter Cohort Study on cyanoacrylate embolization for treatment of refluxing great saphenous veins. J Vasc Surg Venous Lymphat Disord. 2021;9(2):329–334. doi:10.1016/j.jvsv.2020.05.019.
  3. Gibson K, Ferris B. Cyanoacrylate closure of incompetent great, small and accessory saphenous veins without the use of post-procedure compression: Initial outcomes of a post-market evaluation of the VenaSeal system (the WAVES Study). Vascular. 2017;25(2):149–156. doi:10.1177/1708538116651014.
  4. Almeida JI, Javier JJ, Mackay EG, Bautista C, Cher DJ, Proebstle TM. Thirty-sixth month follow-up of first-in-human use of cyanoacrylate adhesive for treatment of saphenous vein incompetence. J Vasc Surg Venous Lymphat Disord. 2017;5(5):658–666. doi:10.1016/j.jvsv.2017.03.016.
  5. Morrison N, Gibson K, Vasquez M, Weiss R, Jones A. Five-year extension study of patients from a randomized clinical trial (VeClose) comparing cyanoacrylate closure versus radiofrequency ablation for the treatment of incompetent great saphenous veins. J Vasc Surg Venous Lymphat Disord. 2020;8(6):978–989. doi:10.1016/j.jvsv.2019.12.080.

  1. Morrison N, Gibson, Vasquez M, et al. VeClose trial 12-month outcomes of cyanoacrylate closure versus radiofrequency ablation for incompetent great saphenous veins. J Vasc Surg. 2017;5(3):321–330. doi:10.1016/j.jvsv.2016.12.005.
  2. Morrison N. VenaSeal closure system vs. radiofrequency ablation for incompetent great saphenous veins (VeClose). 36-month results presented at: IVC; April 20, 2017; Miami, FL.
  3. Proebstle TM, Alm BJ, Gockeritz O, et al. Five-year results from the prospective European multicentre cohort study on radiofrequency segmental thermal ablation for incompetent great saphenous veins. Br J Surg. 2015;102(3):212–218. doi:10.1002/bjs.9679.
  4. Gibson K, Glorieux K. VenaSeal versus ablation with endothermal laser or radiofrequency for saphenous vein incompetence: a comparison of utilization of adjunctive phlebectomy (VenaSeal value). Presented at: AVLS 2019; November 2019; Phoenix, AZ. Abstract available at: journals.sagepub.com/doi/full/10.1177/0268355519893876. Accessed August 28, 2025.